Insulet Corporation $PODD Shares Sold by Munich Reinsurance Co Stock Corp in Munich

Munich Reinsurance Co Stock Corp in Munich trimmed its position in shares of Insulet Corporation (NASDAQ:PODD) by 68.6% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,045 shares of the medical instruments supplier’s stock after selling 11,039 shares during the period. Munich Reinsurance Co Stock Corp in Munich’s holdings in Insulet were worth $768,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Glenmede Investment Management LP raised its holdings in shares of Insulet by 1.6% in the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after buying an additional 35 shares during the period. Curi Capital LLC boosted its holdings in Insulet by 0.8% during the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after acquiring an additional 36 shares during the period. Great Lakes Advisors LLC grew its position in Insulet by 1.5% in the 4th quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock valued at $791,000 after acquiring an additional 40 shares in the last quarter. Camarda Financial Advisors LLC grew its position in Insulet by 0.5% in the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after acquiring an additional 40 shares in the last quarter. Finally, Larson Financial Group LLC increased its stake in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares during the period.

Insulet Stock Down 2.1%

PODD stock opened at $147.48 on Friday. The company’s 50 day moving average price is $154.45 and its 200 day moving average price is $177.72. The firm has a market capitalization of $10.23 billion, a price-to-earnings ratio of 27.57, a PEG ratio of 1.19 and a beta of 1.08. Insulet Corporation has a fifty-two week low of $126.40 and a fifty-two week high of $354.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. During the same quarter in the previous year, the firm earned $1.17 earnings per share. The firm’s quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, equities research analysts anticipate that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PODD has been the topic of several recent research reports. Wells Fargo & Company downgraded shares of Insulet from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $255.00 to $144.00 in a research note on Wednesday, August 5th. Evercore set a $180.00 price target on shares of Insulet in a research report on Monday, July 6th. TD Cowen dropped their price target on shares of Insulet from $294.00 to $144.00 and set a “hold” rating for the company in a research note on Thursday, August 6th. Wall Street Zen lowered Insulet from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 9th. Finally, Canaccord Genuity Group reduced their price objective on Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Fourteen investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Insulet presently has an average rating of “Hold” and an average target price of $195.40.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.